share_log

Truist Securities Maintains Buy on Allogene Therapeutics, Lowers Price Target to $18

Benzinga ·  Jul 12, 2023 11:31

Truist Securities analyst Asthika Goonewardene maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price target from $20 to $18.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment